Brianna Commerford felt a lump. After a few months of feeling mildly ill, she was diagnosed with stage IV Hodgkin’s lymphoma. She was devastated, she was scared, and she was only 9 years old.
Five years later, Brianna is still alive thanks to an experimental treatment she received from the Children’s Oncology Group. Devoted to curing childhood and adolescent cancer, the COG is a clinical trials group that is primarily supported by the U.S. National Institutes of Health (NIH), the largest sponsor of biomedical research in the world.
This month scientists nationwide are petitioning to protect lifesaving research programs like this one before January, when the federal government will automatically slash—or “sequester”—8.2 percent ($2.5 billion) of the NIH budget for 2013 unless Congress stops the move. The money will be withheld because of provisions in the Budget Control Act of 2011 that aimed to cut spending. Combined with the scheduled finale of the Bush-era tax cuts, the provisions are expected to push the country over the now proverbial fiscal cliff.
Separate from the scheduled downsizing of Medicare (2 percent or $14 billion), the NIH cuts threaten to corrode the foundations of biomedical education and research in the U.S. Agencies including the National Science Foundation, NASA and the Department of Defense would also be saddled with lighter coffers. The prospect of deep cuts is particularly alarming to biomedical researchers because the cutbacks would come at a time of already strained budgets.
From 1999 to 2003 the federal allocation for the NIH doubled, which triggered a tremendous boom in the biomedical workforce, according to a 2008 report from an NIH advisory committee. In the years following, though, federal support has failed to keep pace with this expansion in labor; rising inflation and three cuts to the NIH budget in the last seven years have meant that budgeted funds largely go to maintaining the status quo rather than to fresh initiatives.
With fewer awards available, this shortfall has incited fierce competition for federal grants, and consequently the success rate for winning an NIH grant is now at its lowest level in American history. The global financial meltdown of 2008 strained matters further when several private foundations were forced to shut down.
“The sequester could affect both existing and future grants,” says Christy Gullion, an advocate for the University of Washington, which would potentially lose $83 million next year. She has been lobbying in Washington, D.C., since the summer of 2011, when lawmakers resolved the debt-ceiling crisis by passing the Budget Control Act. “We are in uncharted territory if the sequester takes effect.”
Far from the nation’s capital in the birch forests of Maine, many aspiring biologists opt to spend their free hours in the laboratory of Richmond Thompson, a neuroscientist at Bowdoin College. His studies on how different chemicals in the brain—such as vasopressin, vasotocin and testosterone—affect social behavior offer the perfect research opportunity for intrepid minds.
Thompson’s mentorship program receives part of its support from the NSF through its Broader Impacts initiative, which emphasizes undergraduate education and provides monies for students to perform research during the summer.
“At small schools like Bowdoin, we use undergraduates to do a lot of our research,” says Thompson. “If the money starts to disappear, not only does our research start to slow down, but it also means far fewer experiences for undergraduates.”
Another scientist fearing the aftermath of the sequestration is Puneet Opal, a neurologist at Northwestern University who has published an editorial opposing the cuts in The Atlantic. He studies spinocerebellar ataxia type 1 (SCA1), a genetic brain disorder that strikes in adulthood, causing the progressive loss of balance and of muscle control in the face.